Press Releases

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms Full Year Total Revenue Guidance of Between $375 Million

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla. , May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on

CORAL GABLES, Fla. , May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced

The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET CORAL GABLES, Fla. , April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

CORAL GABLES, Fla. , April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare

Achieved Record 2022 Total Net Revenues of $214 Million , a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million , a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product

CORAL GABLES, Fla. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare

The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET CORAL GABLES, Fla. , March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to the Community CORAL GABLES, Fla. , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.

2022 Total Revenues Estimated at $214 Million, Representing 52% YoY Growth Forecast 2023 Total Revenues of Between $375 Million and $385 Million Including FYCOMPA ® , Representing YoY Growth of 75% - 80% 2023 FIRDAPSE ® Net Revenues Estimated at $245 Million to $255 Million 2023 FYCOMPA Net